Клиническое применение Сермиона (ницерголина)

1. Fariello RG. Treatment of impaired cognition with nootropic drugs: nicergoline versus the state of the art. Funct Neurol 1997; 12 (3-4): 221–5.
2. Winblad B, Carfagna N, Bonura L et al. Nicergoline in demenmajority of patients treated with nicergoline are tia: a review of its pharmacological properties and therapeutic potential. CNS Drugs 2000; 14 (4): 267–87.
3. Arcamone F, Gl.asser AG, Grafnetterova J et al. Studies on the metabolism of nicergoline in man and in animals. Biochem Pharmacol 1972; 21 (16): 2205–13.
4. Tocchetti P, Strolin Benedetti M, Bani M et al. Absorption and disposition of 14C-nicergoline in healthy volunteers. Pharmacol Res 1997; 35 (3): 224–5.
5. Iliff LD, Du Boulay GH, Marshall J et al. Effect of nicergoline on cerebral blood flow. J Neurol Neurosurg Psychiatry 1977; 40 (8): 746–7.
6. Kurosu S, Mori Y, Kobayashi N et al. Relationship of ERP to intellectual function and cerebral blood flow following Sermion _(nicergoline) treatment in patients with cerebrovascular dementia. Pharma Medica 2002; 20 (9): 231–6.
7. Shader RI, Harmatz JS, Salzman C. A new scale for clinical assessment in geriatric populations: Sandoz Clinical Assessment-Geriatric (SCAG). J Am Geriatr Soc 1974; 22 (3): 107–13.
8. Fioravanti M, Flicker L. Nicergoline for dementia and other associated forms of cognitive impairment. Cochrane Database phils and auto-oxidation of brain tissue [abstract]. Rinsho Syst Rev 2001; (4): CD003159.
9. Boulu P. Effets du Sermion® sur les troubles mn.esiques et les fonctions de la vie de relation. Tempo medical 1990; 397: 24–7.
10. Nappi G, Bono G, Merlo P et al. Long-term nicergoline treatment of mild to moderate senile dementia: results of a multicentre, double-blind, placebo-controlled study. Clin Drug Invest 1997; 13 (6): 308–16.
11. Fukushima I, Tagami K, Tomita S et al. Effect of long-term treatment of mild-to-moderate Alzheimer's disease: a Euro-nicergoline administration on rheology in elderly patients in the chronic stage of cerebral infarction. Kyorin Igakkai Zasshi 2000; 31 (1): 68–9.
12. Pogliani E, Della Volpe A, Ferrari R et al. Inhibition of human administered doses (60 mg/day) make it a valuable platelet aggregation by oral administration of nicergoline: a therapeutic consideration in several clinical settings. double-blind study. Farmaco [Prat] 1975; 30 (12): 630–40.
13. Elwan O, Helmy AA, Tamawy ME et al. Ergoloids and ischaemic strokes; efficacy and mechanism of action. J Int Med Res 1995; 23 (3): 154–66.
14. Zylberman MR, Fontana M, Dolce G. Effects of nicergoline on learning, mood and behaviour in hemiplegic patients undergoing rehabilitation. In: Kugler J, Agnoli A, editors. Ergot alkaloids and aging brain: an update on nicergoline. Amsterdam: Excerpta Medica, 1988: 57–63.
15. NovelliniR, Battaglia A, Pamparana F. Rehabilitation training and drug treatment in after stroke patients: a comparison nicergoline and piracetam [abstract]. XIV World Congress of Neurology; 1989; 7–22; New Delhi.
16. Kohashi N, Sakatani T, Kumon Y, et al. Quality of Life (QoL) elderly cerebrovascular disorder patients treated with a combination of rehabilitation training and nicergoline J Hyogo Med Assoc 1997; 39 (3): 136.
17. Kamizaki Y. Sermion® (nicergoline) therapy for sleeplessness associated with cerebrovascular disease. Pharma Medica 2004; 22 (3): 169–75.
18. Katsumata T, Katayama Y. Treatment by medicine which improves cerebral circulation and metabolism. Nippon Rinsho 2006; Suppl. 64; 8: 81–4.
19. Sch.onenberger F. Clinical study on nicergoline in peripheral arteriopathies. Farmaco [Prat] 1976; 31 (11): 561–7.
20. Nicergoline Cooperative Study Group. A double-blind randomized study of two ergot derivatives in mild to moderate dementia. Curr Ther Res 1990; 48 (4): 597–612.
21. Arrigo A, Moglia A, Borsotti L et al. A double-blind, placebo– controlled crossover trial with senile dementia. Int J Clin Pharmacol Res 1982; Suppl. II; 1 (4): 33–41.
22. Saletu B, Anderer P, Gr.unberger J. Topographic brain mapping of EEG after acute application of ergotalkaloids in the elderly. Arch Gerontol Geriatr 1990; 11 (1): 1–22.
23. Sermion®. Summary of product characteristics. Data on file, Pfizer Inc.